This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Amphastar (AMPH) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Amphastar's (AMPH) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its pharmaceutical products.
AMPHPositive Net Change MRNAPositive Net Change SRPTPositive Net Change CRSPPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
BeiGene's (BGNE) revenues in fourth-quarter 2023 are expected to have been driven by the sales of its marketed pharmaceutical products.
AMGNNegative Net Change SRPTPositive Net Change BGNEPositive Net Change CRSPPositive Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
VAXART, INC. (VXRT) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
VXRTNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Bayer (BAYRY) Intends to Slash Dividends Amid Challenges
by Zacks Equity Research
Bayer (BAYRY) announced plans to cut dividends to pay out only the legally required minimum for three years in the wake of high debt and increasing legal costs.
BAYRYPositive Net Change SRPTPositive Net Change PBYIPositive Net Change EDITPositive Net Change
biotechnology pharmaceuticals
Roche's (RHHBY) Xolair Gets Approval for Food Allergies
by Zacks Equity Research
Roche (RHHBY) obtains FDA approval for Xolair for the treatment of children and adults with one or more food allergies.
REGNNegative Net Change NVSPositive Net Change RHHBYPositive Net Change PBYIPositive Net Change
biotechnology biotechs pharmaceuticals
Great Lakes Dredge & Dock (GLDD)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
GLDDPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up
by Zacks Equity Research
Sarepta (SRPT) announces the FDA's acceptance of its efficacy supplement to the Elevidys BLA, seeking to expand the treatment label for its DMD drug. The stock gains 8%.
RHHBYPositive Net Change SRPTPositive Net Change ADMAPositive Net Change IMCRPositive Net Change
biotechnology biotechs cell-therapy gene-editing gene-therapy medical pharmaceuticals
Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense
by Zacks Equity Research
Prothena (PRTA) posts a wider-than-expected loss in the fourth quarter on lower revenues and higher costs.
RHHBYPositive Net Change BMYNegative Net Change NVOPositive Net Change PRTAPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow
by Zacks Equity Research
Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024.
MRKPositive Net Change SRPTPositive Net Change CORTNegative Net Change PBYIPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Alnylam (ALNY) Q4 Loss Narrower Than Expected, Stock Dips 10%
by Zacks Equity Research
Alnylam (ALNY) reports mixed fourth-quarter 2023 results, as earnings beat estimates, while revenues miss the same. The stock of the company falls 10%.
REGNNegative Net Change ALNYNegative Net Change NVSPositive Net Change RHHBYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Ultragenyx (RARE) reports better-than-expected fourth-quarter 2023 results, beating both earnings and revenue estimates, driven by strong sales trends of Crysvita and Dojolvi.
REGNNegative Net Change PBYIPositive Net Change RAREPositive Net Change MREOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
New Strong Buy Stocks for February 16th
by Zacks Equity Research
CDNS, ECL, FMX, KRRO and RMR have been added to the Zacks Rank #1 (Strong Buy) List on February 16, 2024.
ECLPositive Net Change FMXPositive Net Change CDNSPositive Net Change RMRPositive Net Change KRRONegative Net Change
biotechnology finance
C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
When C4 Therapeutics, Inc. (CCCC), a clinical-stage biopharmaceutical company, reports fourth-quarter results, the focus will primarily be on pipeline progress.
IONSNegative Net Change NTLAPositive Net Change RCUSPositive Net Change CCCCNo Net Change
biotechnology biotechs
Cedar Fair, L.P. (FUN) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
FUNPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Biotech Stock Roundup: BIIB's Q4 Results, CBAY Up on GILD's Acquisition & Other Updates
by Zacks Equity Research
Earnings from Biogen (BIIB) and CymaBay (CBAY) are in focus in the biotech sector.
BIIBPositive Net Change GILDNegative Net Change VRTXNegative Net Change CBAYPositive Net Change CRSPPositive Net Change
biotechnology biotechs
Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Exact Sciences' (EXAS) revenues in the fourth quarter of 2023 are likely to have been driven by its flagship cancer screening tests, Cologuard and Oncotype DX.
BMRNPositive Net Change MRNAPositive Net Change EXASPositive Net Change NTLAPositive Net Change
biotechnology biotechs earnings medical
Drug, Biotech Stock Q4 Earnings Due on Feb 15: ALNY, BPMC & More
by Zacks Equity Research
Let's look at five biotech/drug companies, ALNY, BPMC, AGIO, CORT and RARE, slated to release quarterly results on Feb 15.
ALNYNegative Net Change CORTNegative Net Change AGIOPositive Net Change RAREPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
BrightSphere Investment Group (BSIG)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
BSIGPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology
by Zacks Equity Research
Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology have been highlighted in this Industry Outlook article.
EXELNegative Net Change SRPTPositive Net Change PBYIPositive Net Change EDITPositive Net Change IMCRPositive Net Change
biotechnology
Zoetis' (ZTS) Q4 Earnings Miss Expectations, Sales Beat
by Zacks Equity Research
Zoetis (ZTS) reports mixed fourth-quarter results, wherein earnings miss estimates while revenues beat the same.
ZTSPositive Net Change PBYIPositive Net Change ADMAPositive Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy CryoPort, Inc. (CYRX) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
CYRXPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline
by Zacks Equity Research
Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.
NVSPositive Net Change BMYNegative Net Change GILDNegative Net Change CBAYPositive Net Change
biotechnology biotechs pharmaceuticals
5 Biotech Stocks to Consider for Your Portfolio in 2024
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR, EDIT and PBYI well amid volatility.
SRPTPositive Net Change EXELNegative Net Change PBYIPositive Net Change EDITPositive Net Change IMCRPositive Net Change
biotechnology biotechs
Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus
by Zacks Equity Research
Immunovant (IMVT) gains 3% on encouraging fiscal third-quarter 2024 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.
PBYIPositive Net Change ADMAPositive Net Change IMVTPositive Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up
by Zacks Equity Research
Corvus' (CRVS) lead candidate, soquelitinib, gets orphan drug designation in the United States. The company???s shares rise 10.75% on the news.
IMGNPositive Net Change SRPTPositive Net Change PBYIPositive Net Change CRVSPositive Net Change
biotechnology biotechs pharmaceuticals